News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
292,487 Results
Type
Article (15105)
Company Profile (295)
Press Release (277087)
Section
Business (86808)
Career Advice (280)
Deals (14874)
Drug Delivery (37)
Drug Development (51229)
Employer Resources (41)
FDA (6197)
Job Trends (6026)
News (155045)
Policy (10777)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (12)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (4)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (1078)
Accelerated approval (2)
Adcomms (12)
Allergies (50)
Alliances (24449)
ALS (61)
Alzheimer's disease (840)
Antibody-drug conjugate (ADC) (79)
Approvals (6201)
Artificial intelligence (133)
Autoimmune disease (8)
Automation (7)
Bankruptcy (108)
Best Places to Work (5363)
BIOSECURE Act (6)
Biosimilars (41)
Biotechnology (242)
Bladder cancer (40)
Brain cancer (20)
Breast cancer (149)
Cancer (1260)
Cardiovascular disease (104)
Career advice (244)
Career pathing (3)
CAR-T (105)
Cell therapy (309)
Cervical cancer (6)
Clinical research (41353)
Collaboration (561)
Compensation (208)
Complete response letters (13)
COVID-19 (1082)
CRISPR (36)
C-suite (139)
Cystic fibrosis (80)
Data (1277)
Denatured (11)
Depression (30)
Diabetes (122)
Diagnostics (1773)
Digital health (6)
Diversity (2)
Diversity, equity & inclusion (10)
Drug discovery (86)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (68)
Earnings (31471)
Editorial (19)
Employer branding (6)
Employer resources (36)
Events (51334)
Executive appointments (414)
FDA (6807)
Featured Employer (36)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (486)
Gene editing (87)
Generative AI (9)
Gene therapy (229)
GLP-1 (372)
Government (1204)
Grass and pollen (2)
Guidances (21)
Healthcare (7650)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (75)
Indications (17)
Infectious disease (1145)
Inflammatory bowel disease (112)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (53)
Interviews (39)
IPO (8219)
IRA (12)
Job creations (999)
Job search strategy (223)
Kidney cancer (6)
Labor market (5)
Layoffs (203)
Leadership (2)
Legal (1545)
Liver cancer (31)
Lung cancer (182)
Lymphoma (80)
Machine learning (1)
Management (11)
Manufacturing (132)
MASH (47)
Medical device (3606)
Medtech (3608)
Mergers & acquisitions (6965)
Metabolic disorders (366)
Multiple sclerosis (49)
NASH (14)
Neurodegenerative disease (54)
Neuropsychiatric disorders (22)
Neuroscience (1201)
NextGen: Class of 2025 (2423)
Non-profit (1197)
Northern California (1539)
Now hiring (21)
Obesity (196)
Opinion (108)
Ovarian cancer (52)
Pain (42)
Pancreatic cancer (53)
Parkinson's disease (101)
Partnered (11)
Patents (101)
Patient recruitment (60)
Peanut (35)
People (27195)
Pharmaceutical (51)
Pharmacy benefit managers (5)
Phase I (14563)
Phase II (19166)
Phase III (12249)
Pipeline (626)
Podcasts (43)
Policy (37)
Postmarket research (882)
Preclinical (6103)
Press Release (35)
Prostate cancer (52)
Psychedelics (35)
Radiopharmaceuticals (217)
Rare diseases (273)
Real estate (1855)
Recruiting (16)
Regulatory (9019)
Reports (15)
Research institute (1144)
Resumes & cover letters (36)
Rett syndrome (3)
RNA editing (2)
RSV (12)
Schizophrenia (54)
Series A (99)
Series B (56)
Service/supplier (1)
Sickle cell disease (38)
Southern California (1364)
Special edition (11)
Sponsored (12)
Startups (2084)
State (1)
Stomach cancer (4)
Supply chain (22)
The Weekly (32)
United States (12338)
Vaccines (215)
Venture capitalists (29)
Webinars (7)
Weight loss (111)
Women's health (15)
Worklife (2)
Date
Today (79)
Last 7 days (406)
Last 30 days (1904)
Last 365 days (21877)
2025 (4126)
2024 (22242)
2023 (24071)
2022 (29875)
2021 (30062)
2020 (25802)
2019 (18776)
2018 (13576)
2017 (15139)
2016 (13125)
2015 (15810)
2014 (11377)
2013 (8362)
2012 (8437)
2011 (8598)
2010 (8076)
Location
Africa (192)
Alabama (41)
Alaska (3)
Arizona (56)
Arkansas (6)
Asia (18948)
Australia (3088)
California (3526)
Canada (1107)
China (314)
Colorado (137)
Connecticut (149)
Delaware (86)
Europe (39977)
Florida (449)
Georgia (101)
Idaho (17)
Illinois (244)
India (10)
Indiana (102)
Iowa (3)
Japan (74)
Kansas (64)
Kentucky (7)
Louisiana (4)
Maine (12)
Maryland (451)
Massachusetts (2728)
Michigan (75)
Minnesota (150)
Mississippi (2)
Missouri (28)
Montana (17)
Nebraska (6)
Nevada (21)
New Hampshire (20)
New Jersey (915)
New Mexico (13)
New York (963)
North Carolina (554)
North Dakota (5)
Northern California (1539)
Ohio (113)
Oklahoma (9)
Oregon (22)
Pennsylvania (689)
Puerto Rico (2)
Rhode Island (17)
South America (256)
South Carolina (5)
Southern California (1364)
Tennessee (34)
Texas (415)
Utah (56)
Virginia (74)
Washington D.C. (30)
Washington State (328)
West Virginia (1)
Wisconsin (20)
292,487 Results for "edge therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500.
May 6, 2024
·
8 min read
Press Releases
Nona Biosciences Integrates Cutting-Edge AI Technology to Enhance Its Fully Human Antibody Platform, Accelerating Antibody Discovery Across Key Therapeutic Areas
March 7, 2025
·
3 min read
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
Edgewise Therapeutics, Inc. today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association Clinical and Scientific Conference.
February 28, 2024
·
4 min read
Drug Development
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)
Edgewise Therapeutics, Inc. today announced an expansion of their clinical development program of EDG-5506.
October 26, 2023
·
10 min read
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the ARCH trial. ARCH is an open label, single-center study assessing safety, tolerability, impact on muscle damage biomarkers, pharmacokinetics (PK) and functional measures with sevasemten (EDG-5506) in adults with Becker.
April 15, 2024
·
12 min read
Press Releases
Cutting-edge Recommendations Provide Treatment Path for Millions of Long COVID Patients
February 12, 2025
·
3 min read
Business
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
October 1, 2024
·
8 min read
Press Releases
Expanding Innovations to Showcase Cutting-Edge Expandable Cage Technology at Spine Summit 2025
February 14, 2025
·
2 min read
Press Releases
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
December 23, 2024
·
11 min read
FDA
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
February 13, 2024
·
7 min read
1 of 29,249
Next
